Comprometidos con Ayudarle a Acceder a los Medicamentos de Genentech

Saber qué esperar puede suponer una gran diferencia. Podemos ayudarle en todos los pasos necesarios para obtener un medicamento de Genentech.

Preguntas Frecuentes

Acerca de PERJETA Access Solutions

PERJETA Access Solutions es un recurso para personas que toman un medicamento de Genentech. Le brindamos acceso al medicamento que necesita.

Me Preocupa Tener Que Pagar PERJETA

Puede haber opciones para ayudarle a conseguir el medicamento de Genentech que le ha prescrito el médico. PERJETA Access Solutions puede derivarle a diversas opciones de asistencia a pacientes.

Cómo Conseguir Mi Medicamento

Podría suceder que no le den el medicamento de Genentech inmediatamente. En primer lugar, la consulta de su médico o la farmacia especializada deberán verificar que su plan de seguro médico cubra esta medicamento. Esto es lo que se llama “investigación de prestaciones” (benefits investigation). Quizá deban también enviar más información antes de que su plan cubra el medicamento. Esto es lo que se llama “autorización previa” (prior authorization).

Cómo Inscribirse en PERJETA Access Solutions

  1. Debe rellenar el formulario llamado PAN.
  2. Su médico debe rellenar el formulario llamado SMN. Usted no tiene que rellenar nada en este formulario.
  3. Su médico envía los dos formularios a PERJETA Access Solutions.

Hay dos formas de rellenar el formulario PAN:

  • Puede rellenar el formulario en línea por internet 
  • Puede descargarlo e imprimirlo para cumplimentarlo en papel

El formulario PAN nos permite comentar su información sobre salud con su médico y su plan de seguro médico. No podemos trabajar con usted sin tener el PAN firmado.

Usted no necesita hacer nada más, pero su médico sí. Debe enviar el formulario llamado Declaración de Necesidad Médica (SMN por sus siglas en inglés). Este formulario nos indica que su médico quiere tratarle con PERJETA. Asegúrese de que el médico nos envía el SMN para que le podamos ayudar.

Usted no tiene que rellenar nada en el formulario SMN.

Mi Plan Médico ha Rechazado la Cobertura de PERJETA

Si su plan de seguro médico no cubre el medicamento de Genentech, usted y la consulta de su médico pueden realizar una apelación. Consulte a su médico para saber si necesita presentar una petición.

Disponemos de recursos para ayudarle a usted y a su médico a realizar una apelación.

Disponemos de recursos para ayudarle a usted y a su médico a realizar una apelación. Usted o la consulta de su médico debe realizar una apelación directamente con su plan de seguro médico.

Esto depende de su plan de seguro médico. Debe preguntar directamente a su plan cuál es su proceso. En ocasiones el proceso de apelación es rápido. No obstante, una apelación puede tardar varios meses si apela varias veces.

Mi Seguro Médico Puede Cambiar

Si su seguro cambia mientras está tomando un medicamento de Genentech, llámenos. Podemos ayudarle a comprender su nueva cobertura.

La GATCF ayuda a las personas que no tienen seguro médico. También ayuda a las personas que, aun contando con un seguro médico, tienen dificultades para pagar sus medicamentos de Genentech. Si reúne los requisitos de la GATCF, podría recibir el medicamento de forma gratuita.

Es responsabilidad suya y de su médico cumplimentar y enviar toda la documentación necesaria a su plan de seguro médico. Genentech no puede garantizar que su plan cubra los tratamientos.

PAN=siglas en inglés de Autorización del Paciente y Aviso de Solicitud Para Transmitir Información Médica a Genentech Access Solutions y a Genentech® Access to Care Foundation.

SMN=siglas en inglés de Declaración de Necesidad Médica.

Important Safety Information & Indication

What it Treats

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

  • use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. 
  • use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

PERJETA® is approved for use in combination with Herceptin® and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects of PERJETA?

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
  • Based on test results, your doctor may hold or discontinue treatment with PERJETA

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. This process can cause reactions known as infusion-related reactions. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis. These reactions may be severe, may happen quickly, and may affect many areas of the body

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are:

  • Hair loss
  • Low levels of white blood cells with or without fever
  • Diarrhea
  • Nausea

The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are:

  • Diarrhea
  • Nausea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Vomiting
  • Feeling tired

The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Nausea
  • Feeling tired
  • Vomiting
  • Low levels of red blood cells
  • Low platelet count

The most common side effects of PERJETA when given with Herceptin and paclitaxel following 4 cycles of dose-dense doxorubicin and cyclophosphamide as part of an early breast cancer regimen before surgery are:

  • Nausea
  • Diarrhea
  • Hair loss
  • Feeling tired
  • Constipation
  • Damage to the nerves (numbness, tingling, pain in hands/feet)
  • Headache

The most common side effects of PERJETA when given with Herceptin and docetaxel following 4 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are:

  • Diarrhea
  • Nausea
  • Hair loss
  • Weakness
  • Constipation
  • Feeling tired
  • Mouth blisters or sores
  • Vomiting
  • Pain in the muscles
  • Low levels of red blood cells

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:

  • Diarrhea
  • Nausea
  • Hair Loss
  • Feeling tired
  • Damage to the nerves (numbness, tingling, pain in hands/feet)
  • Vomiting

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects